Related Experiment Video
Updated: Nov 18, 2025

Knee Arthrocentesis in Adults
Published on: February 25, 2022
Arterial Thrombotic Events in Adult Inpatients With COVID-19
Morgane Fournier1, Dorothée Faille2, Antoine Dossier1
1Département de Médecine Interne, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, France.
Insights
Arterial thrombotic events occurred in 5.6% of hospitalized COVID-19 patients, increasing mortality risk. Elevated D-dimer levels over 1250 ng/mL identified high-risk individuals for these dangerous events.
Area of Science:
- Cardiology
- Infectious Diseases
- Vascular Medicine
Background:
- Coronavirus disease 2019 (COVID-19) is associated with a hypercoagulable state.
- Arterial thrombotic events (ATEs) are a serious complication of COVID-19 infection.
- Understanding risk factors for ATEs in COVID-19 patients is crucial for clinical management.
Purpose of the Study:
- To evaluate the clinical course of arterial thrombotic events in adult inpatients with COVID-19.
- To identify risk factors associated with the occurrence of ATEs in COVID-19 patients.
- To assess the impact of ATEs on mortality in hospitalized COVID-19 patients.
Main Methods:
- Retrospective analysis of consecutive adult COVID-19 patients admitted to a French referral center.
- Data collection on demographic, clinical, laboratory, and treatment variables.
- Analysis of arterial thrombotic events occurring from admission through discharge.
Main Results:
- Among 531 COVID-19 patients, 5.6% experienced ATEs.
- ATEs occurred at a median of 11 days post-symptom onset and were associated with traditional cardiovascular risk factors.
- Patients with ATEs had a 3-fold increased risk of in-hospital death (HR 2.96).
- D-dimer levels >1250 ng/mL significantly increased the risk of ATEs (SHR 7.68).
Conclusions:
- Hospitalized COVID-19 patients experiencing ATEs have a dramatically high in-hospital mortality rate.
- Elevated D-dimer levels (>1250 ng/mL) at admission may identify COVID-19 patients at increased risk for ATEs.
- Early identification and management of ATE risk factors are essential in COVID-19 care.
Objective:
To evaluate the clinical course of and risk factors for arterial thrombotic events in adult inpatients with coronavirus disease 2019 (COVID-19).
Methods:
All consecutive adult patients admitted for COVID-19 infection in a referral center in France and discharged from the hospital between April 1 and April 30, 2020, were included. All arterial thrombotic events that occurred through discharge were considered for analysis. Epidemiologic, demographic, clinical, laboratory, treatment, and outcome data were extracted from electronic medical records with use of a standardized data collection form.
Results:
Overall, 531 COVID-19+ patients were analyzed. Among them, 30 (5.6%) experienced arterial thrombotic events. Arterial thrombotic events in the setting of COVID-19 infection happened at a median of 11 (5-20) days after the first symptoms of infection; occurred in high-risk patients according to traditional cardiovascular risk factors; had an atypical pattern, such as thrombosis of the aorta, upper limb, or renal arteries or cerebral microvasculopathy in 7 (23.3%) cases; and were associated with an in-hospital mortality rate of 40%. Arterial thrombotic events increased the risk of death by 3-fold in COVID-19+ patients (hazard ratio, 2.96; 95% CI, 1.4 to 4.7; P=.002). A subdistribution survival hazard model showed that a concentration of D-dimer above 1250 ng/mL increased the risk of arterial thrombotic events in COVID-19+ patients by more than 7 (subdistribution hazard ratio, 7.68; 95% CI, 2.9 to 20.6; P<.001).
Conclusion:
A dramatically high rate of in-hospital death was observed in patients who suffered arterial thrombotic events in the setting of COVID-19 infection. A D-dimer level above 1250 ng/mL at entry may identify COVID-19+ patients at risk for arterial thrombotic events.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis IV: Nursing Management
Venous Thrombosis I: Introduction
Anticoagulant Drugs: Low-Molecular-Weight Heparins

